Pregnancy hepatitis b drug showdown: which is safer for mom and baby?
NCT ID NCT07542951
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two antiviral medications, TAF and TDF, in 200 pregnant women with chronic hepatitis B. The goal is to see which drug better prevents passing the virus to the baby and causes fewer birth defects or side effects. Participants take the drug daily during pregnancy and have regular checkups until after birth.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B VIRUS INFECTION; PREGNANT WOMEN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Infectious Diseases, Guangdong Provincial Key Laboratory of Major Obstetric Diseases; Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, The Third Affiliated Hospital, Guangzhou Medical University,
Guangzhou, Guangdong, 450000, China